Alk, officially known as Alk Abello A/S, is a leading player in the biopharmaceutical industry, headquartered in Denmark (DK). Founded in 1923, the company has established itself as a pioneer in allergy immunotherapy, focusing on innovative treatments for allergic conditions. With a strong presence in Europe and North America, Alk is dedicated to improving the quality of life for allergy sufferers through its advanced products.
The company’s core offerings include sublingual and injectable immunotherapy solutions, which are distinguished by their efficacy and patient-friendly administration methods. Alk's commitment to research and development has positioned it as a market leader, achieving significant milestones such as the introduction of the first sublingual tablet for grass pollen allergy. With a robust portfolio and a focus on patient-centric solutions, Alk continues to drive advancements in allergy treatment.
-8 vs industry average
Alk’s score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alk?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Alk's reported carbon emissions
In 2023, ALK-Abelló A/S reported total carbon emissions of approximately 69.6 million kg CO2e. This figure includes Scope 1 emissions of about 5.1 million kg CO2e, Scope 2 emissions of approximately 0.4 million kg CO2e, and Scope 3 emissions amounting to around 64.1 million kg CO2e. The company has made significant strides in reducing its carbon footprint, achieving a 41% reduction in absolute Scope 1 and Scope 2 emissions from a 2019 baseline by the end of 2022. Looking ahead, ALK-Abelló A/S has committed to further reductions, targeting a 42% decrease in absolute Scope 1 and 2 greenhouse gas emissions by 2030, using 2022 as the base year. Additionally, the company aims for 80% of its suppliers, covering various emissions categories, to establish science-based targets by 2028. These commitments align with the Science Based Targets initiative (SBTi) and reflect the company's dedication to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Alk’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Alk yet.
Scope 3 top emissions categories
9 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Alk
Frequently asked questions
Common questions about Alk’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project